Trials / Completed
CompletedNCT00696332
Talampanel for Amyotrophic Lateral Sclerosis (ALS)
A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of Talampanel in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 559 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy, tolerability and safety of oral administration of talampanel compared to a placebo in subjects with ALS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talampanel | capsules Talampanel, 3 times per day, 52 weeks |
| DRUG | Talampanel | capsules Talampanel, 3 times per day, 52 weeks |
| OTHER | placebo | capsules, placebo, 3 times a day, for 52 weeks |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2010-04-01
- Completion
- 2010-05-01
- First posted
- 2008-06-12
- Last updated
- 2011-10-21
Locations
24 sites across 10 countries: United States, Belgium, Canada, France, Germany, Hungary, Israel, Italy, Netherlands, Spain
Source: ClinicalTrials.gov record NCT00696332. Inclusion in this directory is not an endorsement.